{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:34:20Z","timestamp":1789162460047,"version":"build-2803163510"},"reference-count":33,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,1,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although the prognosis of chronic myeloid leukemia (CML) patients treated with imatinib is good, many fail to develop an optimal response or lose one. This heterogeneity could be attributed to the presence of human organic cation transporter-1 (hOCT1) single nucleotide polymorphisms (SNPs). In the present study, we analyzed the effect of 23 hOCT1 SNPs on imatinib treatment outcome in newly diagnosed CML patients using MassARRAY sequencing and pyrosequencing. The only SNP associated with outcome was M420del (rs35191146), with patients with the M420del demonstrating an increased probability of imatinib treatment failure. In CML cell lines transfected with M420del and\/or M408V, M420del significantly decreased imatinib uptake, but this effect was countered if the M408V (rs628031) SNP was also present. A similar effect was seen for the uptake of the hOCT1 substrates TEA+ and ASP+. Finally, apparent hOCT1 mRNA levels were studied using both our earlier primers covering the M420del and another set that did not. Different mRNA expression was observed, explaining the disparity in published data on the prognostic importance of hOCT1 mRNA and highlighting the importance of avoiding common SNP sites in primer design. These data demonstrate that the common M420del SNP can modulate the outcome of imatinib treatment.<\/jats:p>","DOI":"10.1182\/blood-2012-01-405035","type":"journal-article","created":{"date-parts":[[2012,12,6]],"date-time":"2012-12-06T02:49:16Z","timestamp":1354762156000},"page":"628-637","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":60,"title":["The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia"],"prefix":"10.1182","volume":"121","author":[{"given":"Athina","family":"Giannoudis","sequence":"first","affiliation":[{"name":"Section of Haematology, Molecular and Clinical Cancer Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Wang","sequence":"additional","affiliation":[{"name":"Section of Haematology, Molecular and Clinical Cancer Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Jorgensen","sequence":"additional","affiliation":[{"name":"Department of Biostatistics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Xinarianos","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Davies","sequence":"additional","affiliation":[{"name":"Section of Haematology, Molecular and Clinical Cancer Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep","family":"Pushpakom","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Triantafilos","family":"Liloglou","sequence":"additional","affiliation":[{"name":"Cancer Research UK Centre, Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieying-Eunice","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Austin","sequence":"additional","affiliation":[{"name":"Section of Haematology, Molecular and Clinical Cancer Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa L.","family":"Holyoake","sequence":"additional","affiliation":[{"name":"Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Foroni","sequence":"additional","affiliation":[{"name":"Imperial College London, Faculty of Medicine, Hammersmith Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis D.","family":"Kottaridis","sequence":"additional","affiliation":[{"name":"Department of Haematology, Royal Free Hospital, London, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"III Medizinische Klinik, Universit\u00e4tsmedizin Mannheim, Universit\u00e4t Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munir","family":"Pirmohamed","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Clark","sequence":"additional","affiliation":[{"name":"Section of Haematology, Molecular and Clinical Cancer Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2019111809440692400_B1","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance.","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"issue":"16","key":"2019111809440692400_B2","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","article-title":"Functional activity of the OCT1 protein is predictive of long term outcome in patients with chronic phase chronic myeloid leukaemia treated with imatinib.","volume":"28","author":"White","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111809440692400_B3","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","article-title":"Expression of the uptake drug transporter hOCT1 is an important determinant of the response to imatinib in chronic myeloid leukaemia.","volume":"83","author":"Wang","year":"2008","journal-title":"Clin Pharm Therap"},{"issue":"10","key":"2019111809440692400_B4","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year follow-up.","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"issue":"20","key":"2019111809440692400_B5","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111809440692400_B6","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/leu.2008.225","article-title":"A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials.","volume":"22","author":"Lucas","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"2019111809440692400_B7","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"2019111809440692400_B8","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1365-2141.2011.08653.x","article-title":"Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study.","volume":"155","author":"Gallipoli","year":"2011","journal-title":"Br J Haematol"},{"issue":"8","key":"2019111809440692400_B9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/00008571-200211000-00002","article-title":"Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences.","volume":"12","author":"Kerb","year":"2002","journal-title":"Pharmacogenetics"},{"issue":"3","key":"2019111809440692400_B10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.bbrc.2003.11.175","article-title":"Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions.","volume":"313","author":"Sakata","year":"2004","journal-title":"Biochem Biophys Res Comm"},{"issue":"6","key":"2019111809440692400_B11","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/tpj.2010.54","article-title":"Genotype dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions.","volume":"11","author":"Ahlin","year":"2011","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"2019111809440692400_B12","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1172\/JCI30558","article-title":"Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.","volume":"117","author":"Shu","year":"2007","journal-title":"J Clin Invest"},{"issue":"2","key":"2019111809440692400_B13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/sj.clpt.6100275","article-title":"Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics.","volume":"83","author":"Shu","year":"2008","journal-title":"Clin Pharm Therap"},{"issue":"14","key":"2019111809440692400_B14","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","article-title":"Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to matinib therapy in chronic myeloid leukaemia.","volume":"15","author":"Kim","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2019111809440692400_B15","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/leu.2010.86","article-title":"hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukaemia.","volume":"24","author":"Bazeos","year":"2010","journal-title":"Leukemia"},{"issue":"11","key":"2019111809440692400_B16","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1038\/leu.2010.188","article-title":"OCT1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT1.","volume":"24","author":"White","year":"2010","journal-title":"Leukemia"},{"issue":"8","key":"2019111809440692400_B17","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.leukres.2010.12.004","article-title":"Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia.","volume":"35","author":"Maffioli","year":"2011","journal-title":"Leuk Res"},{"issue":"10","key":"2019111809440692400_B18","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/FPC.0b013e3283311347","article-title":"Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy.","volume":"19","author":"Zhang","year":"2009","journal-title":"Pharmacogenet Genomics"},{"issue":"8","key":"2019111809440692400_B19","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1182\/blood-2007-10-116236","article-title":"Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia.","volume":"112","author":"Giannoudis","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2019111809440692400_B20","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: Higher doses of imatinib may overcome the negative impact of low OCT-1 activity.","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2019111809440692400_B21","doi-asserted-by":"crossref","first-page":"C1521","DOI":"10.1152\/ajpcell.00622.2005","article-title":"Characterisation of regulatory mechanisms and states of human organic cation transporter 2.","volume":"290","author":"Biermann","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"issue":"6","key":"2019111809440692400_B22","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.bcp.2011.12.032","article-title":"Lamotrigine is a substrate for OCT1 in brain endothelial cells.","volume":"83","author":"Dickens","year":"2012","journal-title":"Biochem Pharm"},{"key":"2019111809440692400_B23","article-title":"A package for survival analysis in S. 2012.","author":"Therneau"},{"issue":"3","key":"2019111809440692400_B24","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A Class of K-sample tests for comparing the cumulative incidence of a competing risk.","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"2019111809440692400_B25","article-title":"Package \u2018cmprsk\u2019: Subdistribution analysis of competing risks.","author":"Gray","journal-title":"R Package Version 2.2-2"},{"issue":"10","key":"2019111809440692400_B26","doi-asserted-by":"crossref","first-page":"5902","DOI":"10.1073\/pnas.0730858100","article-title":"Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1.","volume":"100","author":"Shu","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"446","key":"2019111809440692400_B27","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"2019111809440692400_B28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1124\/jpet.110.170159","article-title":"Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function.","volume":"335","author":"Chen","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"2019111809440692400_B29","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.2337\/db08-0896","article-title":"Reduced function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: A GoDARTS study.","volume":"58","author":"Zhou","year":"2009","journal-title":"Diabetes"},{"issue":"11","key":"2019111809440692400_B30","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1080\/10428190802322893","article-title":"R61C polymorphism and response to imatinib treatment in chronic myeloid leukaemia patients.","volume":"49","author":"Zach","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2019111809440692400_B31","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/leu.2009.166","article-title":"Nilotinib concentration in cell lines and CD34+ CML cells is not mediated by active uptake or efflux by major drug transporters.","volume":"23","author":"Davies","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"2019111809440692400_B32","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1681\/ASN.2004040256","article-title":"Individual PKC-phosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation.","volume":"16","author":"Ciarimboli","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"2019111809440692400_B33","doi-asserted-by":"crossref","first-page":"E204","DOI":"10.1210\/jc.2010-0145","article-title":"Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome.","volume":"95","author":"Gambineri","year":"2010","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/4\/628\/1366922\/zh800413000628.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/4\/628\/1366922\/zh800413000628.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T10:38:02Z","timestamp":1574073482000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/121\/4\/628\/31233\/The-hOCT1-SNPs-M420del-and-M408V-alter-imatinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,24]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,1,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-01-405035","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,24]]}}}